A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis

Starting soon

Conditions studied: Psoriasis Arthritis

In brief

The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care. The main questions are: * Do treatment responses differ according to the number of previous advanced therapies? * Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness? Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development. Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.

Key facts

Study ID

NCT07417995

Run by

Royal United Hospitals Bath NHS Foundation Trust

People needed

400

Starts

2026-06-01

Expected to finish

2027-06-01

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Clinical diagnosis of PsA meeting CASPAR criteria
• Starting a new b/tsDMARD, irrespective of line of therapy

You may not qualify if…

• Switching b/tsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis.
• Previous treatment with the same b/tsDMARD being started at baseline.
• Inability or unwillingness to provide informed consent.

Where it is running

• Royal United Hospitals Bath NHS Foundation Trust — Bath, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.